Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 13/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 13/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 13/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 13/20 | 1.00 |
| ▸ | PDE5A | O76074 | 12/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.50 |
| ▸ | PCK1 | P35558 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7269780 | 0.94 | PDE4A (0.89) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7270168 | 0.94 | PDE4A (0.89) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7268220 | 0.93 | PDE4A (0.87) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7026234 | 0.82 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7809025 | 0.82 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7345938 | 0.79 | PDE5A (0.66) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL13986185 | 0.79 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL13986122 | 0.79 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7027210 | 0.79 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7025747 | 0.78 | ADORA1 (0.64) | PDE4APDE4BPDE4CPDE4DPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3499 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026043843-A1 | TETRAHYDROPYRIMIDINE (THP) IONIZABLE LIPIDS FOR EFFICIENT MRNA DELIVERY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2026-02-26 | — | — | WO | claimed |
| WO-2024215771-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2024-10-17 | — | — | WO | claimed |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| EP-4262812-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | Southern Research Institute (US) | 2023-10-25 | — | — | EP | claimed |
| WO-2023122212-A2 | SUBSTITUTED PHENYL ETHYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-29 | — | — | WO | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| EP-4125845-A1 | NOVEL 2-PYRIMIDONE ANALOGS AS POTENT ANTIVIRAL AGENTS AGAINST ALPHAVIRUSES | Southern Research Institute (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| EP-1025103-A1 | NOVEL POLYMORPHIC FORMS OF CIPAMFYLLINE | SmithKline Beecham Corporation (US) | 2000-08-09 | — | — | EP | claimed |
| US-5981535-A | FOR TREATMENT OF ALLERGIC DISORDERS ASSOCIATED WITH ATOPY, BRONCHODILATION TO TREAT DISORDERS OF THE RESPIRATORY TRACT IN A MAMMAL | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-11-09 | — | — | US | claimed |
| WO-1999020625-A1 | NOVEL POLYMORPHIC FORMS OF CIPAMFYLLINE | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-29 | — | — | WO | claimed |
| WO-1999020280-A1 | NOVEL USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-29 | — | — | WO | claimed |
| US-5734051-A | TREATMENT OF CEREBROVASCULAR DISORDERS AND-OR DISORDERS ASSOCIATED WITH CEREBRAL SENILITY | BEECHAM GROUP (GB) | 1998-03-31 | — | — | US | claimed |
| EP-0558659-A4 | TNF INHIBITORS | — | 1993-10-20 | — | — | EP | claimed |
| EP-0558659-A1 | TNF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-08 | — | — | EP | claimed |
| WO-1993016699-A1 | TNF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-02 | — | — | WO | claimed |
| WO-1992009203-A1 | TNF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-11 | — | — | WO | claimed |
| EP-0389282-A2 | Xanthinederivatives, process for their preparation and their pharmaceutical use | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1990-09-26 | — | — | EP | claimed |